The link to the media availability below has been corrected.

April 22, 2021

Contact: OHA External Relations, orcovid19.media@dhsoha.state.or.us

OHA, CDC investigating death of resident following Johnson & Johnson COVID-19 vaccination

PORTLAND, Ore.—Oregon Health Authority has been informed that the Centers for Disease Control and Prevention is investigating the death of an Oregon woman this week following immunization with Johnson & Johnson’s COVID-19 vaccine.

Information about the death has been sent to the CDC through the Vaccine Adverse Event Reporting System (VAERS), the national reporting system used to collect reports of adverse events after vaccination.

OHA was notified of the potential adverse event on April 20, two days after the CDC was notified on April 18. The Oregon resident, a woman in her 50s, received a dose of the Johnson & Johnson COVID-19 vaccine before the pause order on its use was issued. Until the investigation is complete, it cannot be concluded whether her death is related to the vaccine.

She developed a rare but serious blood clot within two weeks following vaccination. This blood clot was seen in combination with very low platelets. Prior to the issuance of the pause, cases of this serious blood clot had been identified among six women around the country who received the vaccine.

Health care providers are required to report certain adverse events after COVID-19 vaccines, in accordance with the emergency use authorization (EUA) for COVID-19 vaccines. These include serious adverse events, such as death, any life-threatening event and inpatient hospitalization. At the time of the CDC–FDA pause recommendation, about 7.5 million doses of the Johnson & Johnson vaccine had been administered in the United States, with more than 87,000 doses having been administered at locations throughout Oregon.

The case in Oregon will add to the evidence of potential risk associated with Johnson & Johnson vaccine. The Advisory Committee on Immunization Practices (ACIP) will review the data accumulated to date and weigh the risks and benefits of the vaccine. These considerations will inform the ACIP’s recommendations regarding use of the vaccine going forward.

The CDC and OHA will provide updates on any developments as they can be shared during the review and investigation process.

OHA continues to encourage all Oregonians to schedule an appointment to receive a COVID-19 vaccination when appointments become available.

Media are invited to attend a media briefing at 4 p.m. today with Dr. Shimi Sharief, senior health advisor with the Oregon Health Authority.

Dr. Sharief will answer medical questions about the potential adverse event following the immunization with Johnson & Johnson’s COVID-19 vaccine. Media will be able to join via this Zoom link. Media can also join by calling 669 254 5252; meeting ID: 161 615 5257; passcode: 218011.